medulloblastoma cells which had a distinct chemokine signature, producing MCP-1; Gro-a; MIF; IL-8; Serpin E1; and IL-6 [quantified in Figure 3B]. (TIF) Figure S2 Chemokine protein profiler membranes showed that while RANTES was near undetectable in supernatant from bEND.3 or in supernatant from Daoy, its secretion substantially increased as early as 48 hours of Daoy and bEND.3 coculture and rapidly increased over time to plateau after 6 days. Other chemokines/ chemo-attractant molecules that were present in a low concentra- tion but progressively increased in coculture were also present at low concentrations in Daoy only supernatants and increased to higher levels in proportion to the degree of confluency of the Daoy cells. (TIF) Figure S3 In Daoy and HBMEC cocultures, RANTES appeared anew on days 2–4 of co-culture and its levels References 1. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239–252. 2. Laconi E, Doratiotto S, Vineis P (2008) The microenvironments of multistage carcinogenesis. Semin Cancer Biol 18: 322–329. 3. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, et al. (2004) Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 199: 1213–1221. 4. Desfrancois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, et al. (2010) Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS One 5: e8437. 5. Denkert C, Loibl S, Noske A, Roller M, Muller BM, et al. (2010) Tumor- associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105–113. 6. Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT, et al. (2010) Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 7. Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, et al. (2009) Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 115: 2891–2902. 8. Deschoolmeester V, Baay M, Van ME, Weyler J, Vermeulen P, et al. (2010) Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 11: 19. 9. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, et al. (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27: 5944–5951. 10. Zancope E, Costa NL, Junqueira-Kipnis AP, Valadares MC, Silva TA, et al. (2010) Differential infiltration of CD8+ and NK cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med 39: 162–167. 11. Kwong BY, Roberts SJ, Silberzahn T, Filler RB, Neustadter JH, et al. (2010) Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. J Invest Dermatol 130: 1726–1736. 12. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA (2010) Leukocytic promotion of prostate cellular proliferation. Prostate 70: 377–389. 13. Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31: 249–256. 14. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587–596. 15. Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272: 60–66. 16. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, et al. (2008) Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 9: 137–145. 17. Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, et al. (1997) Functional expression of the eotaxin receptor CCR3 in T lymphocytes co- localizing with eosinophils. Curr Biol 7: 836–843. 18. Hansson GK (1999) Inflammation and immune response in atherosclerosis. Curr Atheroscler Rep 1: 150–155. 19. Laudanna C, Alon R (2006) Right on the spot. Chemokine triggering of integrin- mediated arrest of rolling leukocytes. Thromb Haemost 95: 5–11. 20. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868–874. Tumor/Endothelium Crosstalk Attracts T Cells increased rapidly 6 days after co-culture, as determined by a human RANTES-specific ELISA. (TIF) Acknowledgments We thank Malcolm K. Brenner for the helpful discussion, advice, and critical review of the manuscript. We would also like to thank Drs. Serena K. Perna and Aaron E. Foster for reviewing the final manuscript and Awateef Akrabi for assistance with FACS analysis. Author Contributions Conceived and designed the experiments: VSS DRS HK LSM KH HEH SG NA. Performed the experiments: VSS KKHC DRS HK XNL CG LP XG MB NA. Analyzed the data: VSS HK XNL LSM MB KH SG NA. Contributed reagents/materials/analysis tools: DRS XNL LP LSM SG. Wrote the paper: VSS KKHC DRS LSM HEH SG NA. 21. Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25: 313–319. 22. Omari KM, John GR, Sealfon SC, Raine CS (2005) CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 128: 1003–1015. 23. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, et al. (1997) High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 100: 1137–1143. 24. Vaday GG, Franitza S, Schor H, Hecht I, Brill A, et al. (2001) Combinatorial signals by inflammatory cytokines and chemokines mediate leukocyte interac- tions with extracellular matrix. J Leukoc Biol 69: 885–892. 25. Nikitenko LL (2009) Vascular endothelium in cancer. Cell Tissue Res 335: 223–240. 26. Borovski T, Verhoeff JJ, ten CR, Cameron K, de Vries NA, et al. (2009) Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. Int J Cancer 125: 1222–1230. 27. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10: 505–514. 28. Lefort CT, Kim M (2010) Human T lymphocyte isolation, culture and analysis of migration in vitro. J Vis Exp. 29. Vishwanath RP, Brown CE, Wagner JR, Meechoovet HB, Naranjo A, et al. (2005) A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells. J Immunol Methods 302: 78–89. 30. Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, et al. (2008) Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res 14: 3832–3839. 31. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, et al. (2009) Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol 6: 53–58. 32. Fisher DT, Chen Q, Appenheimer MM, Skitzki J, Wang WC, et al. (2006) Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol Invest 35: 251–277. 33. Heeger P, Wolf G, Meyers C, Sun MJ, O’Farrell SC, et al. (1992) Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes. Kidney Int 41: 220–225. 34. Schall TJ, Simpson NJ, Mak JY (1992) Molecular cloning and expression of the murine RANTES cytokine: structural and functional conservation between mouse and man. Eur J Immunol 22: 1477–1481. 35. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, et al. (1994) Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33: 14144–14155. 36. Appay V, Rowland-Jones SL (2001) RANTES: a versatile and controversial chemokine. Trends Immunol 22: 83–87. 37. Javeed A, Zhao Y, Zhao Y (2008) Macrophage-migration inhibitory factor: role in inflammatory diseases and graft rejection. Inflamm Res 57: 45–50. 10.1007/ s00011-007-7110-6 [doi]. 38. Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, et al. (2003) Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor- associated angiogenesis. Ann N Y Acad Sci 995: 171–182. 39. Schwartz V, Lue H, Kraemer S, Korbiel J, Krohn R, et al. (2009) A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 583: 2749–2757. S0014-5793(09)00611-5 [pii];10.1016/j.febslet.2009.07.058 [doi]. PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e20267